



# **tTF-NGR - translating a CD13-targeted pro-coagulatory molecule from lab to clinic**




10.09.2024


# Mechanistic principle of anti-vascular tTF-NGR



# Initiation of the extrinsic coagulation cascade by tTF-NGR



# Tumor cells starved by infarction



## **tTF-NGR – timeline idea to clinic**

---

**1999 Start of experimentation**

**2006 Preclinical *in vitro* and *in vivo* data with tTF-NGR completed**

**2011 GMP production facility and process**

**2012 Application for funding of animal safety, GMP, and phase I**

**2016 GMP manufacturers license**

**2016 Completion of safety pharmacology, 4 species**

**2016 Approval phase I study, Eudra-CT 2016-003042-85**


**2019 Phase I trial completed**

**2021 Safety cohort of randomized TRABTRAP study started, EU CT 2024-516392-33-00**

# TRABTRAP phase III – efficacy cohort



## > Efficacy and tolerability



→ open, randomised,  
controlled  
multicenter study  
→ 12 centers in  
Germany

Stratification according to  
- **CD13+ grade 1 and 2 versus 3**  
- **number of previous regimen**

### Primary objective of phase III

- ✓ Prolongation of PFS by the combination of Trabectedin and tTF-NGR (>4 months)